1 asset in Pediatric Osteosarcoma

Therapeutic assets addressing Pediatric Osteosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Pediatric Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)